Open Federal Grants · National Institutes of Health
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health · Opportunity PAR-25-070 · Award amount: see the official listing
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-b
Eligibility text quoted from the official Grants.gov listing.
About This Opportunity
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The …
Description from the official Grants.gov listing — read the complete notice, including any updates, on Grants.gov before applying.
More Open Grants From NIH
Browse Open Grants
By who can apply:
By agency:
By closing month:
Every grant listed here comes from Grants.gov, the official U.S. government database. Award amounts and deadlines can change — verify the details on the official listing before you apply. GrantRound is not affiliated with the U.S. government.